Cellectis S.A. (CLLS) and Global Blood Therapeutics Inc. (NASDAQ:GBT) Comparing side by side

This is therefore a comparing of the institutional ownership, analyst recommendations, profitability, risk, dividends, earnings and valuation in Cellectis S.A. (NASDAQ:CLLS) and Global Blood Therapeutics Inc. (NASDAQ:GBT). The two are both Biotechnology companies that compete with one another.

Earnings & Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Cellectis S.A. 25.47M 29.63 82.53M -2.11 0.00
Global Blood Therapeutics Inc. N/A 0.00 166.24M -3.42 0.00

Table 1 showcases the gross revenue, earnings per share (EPS) and valuation of Cellectis S.A. and Global Blood Therapeutics Inc.


Table 2 hightlights the net margins, return on equity and return on assets of the two companies.

Net Margins Return on Equity Return on Assets
Cellectis S.A. -324.03% -23% -18.8%
Global Blood Therapeutics Inc. 0.00% -36.2% -33.6%

Volatility and Risk

A 1.7 beta indicates that Cellectis S.A. is 70.00% more volatile compared to Standard and Poor’s 500. Competitively, Global Blood Therapeutics Inc. is 210.00% more volatile than Standard and Poor’s 500, because of the 3.1 beta.


The Current Ratio and a Quick Ratio of Cellectis S.A. are 11.2 and 11.2. Competitively, Global Blood Therapeutics Inc. has 14.6 and 14.6 for Current and Quick Ratio. Global Blood Therapeutics Inc.’s better ability to pay short and long-term obligations than Cellectis S.A.

Analyst Ratings

The following table delivered below contains the ratings and recommendations for Cellectis S.A. and Global Blood Therapeutics Inc.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Cellectis S.A. 0 1 0 2.00
Global Blood Therapeutics Inc. 0 0 0 0.00

Cellectis S.A. has an average target price of $25, and a 41.24% upside potential.

Institutional and Insider Ownership

Roughly 29.4% of Cellectis S.A. shares are held by institutional investors while 14.72% of Global Blood Therapeutics Inc. are owned by institutional investors. Competitively, Global Blood Therapeutics Inc. has 4.6% of it’s share held by insiders.


Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Cellectis S.A. -12.03% -27.86% -25.47% -35.88% -21.71% -33.55%
Global Blood Therapeutics Inc. 37.54% 4.05% -4.87% -5.28% -1.07% 10.24%

For the past year Cellectis S.A. had bearish trend while Global Blood Therapeutics Inc. had bullish trend.


On 7 of the 10 factors Cellectis S.A. beats Global Blood Therapeutics Inc.

Cellectis S.A., a gene-editing company, develops and sells immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer in France. The company operates through two segments, Therapeutics and Plants. Its lead product candidate is UCART19, an allogeneic T-cell product candidate for the treatment of CD19 expressing hematologic malignancies, which develop in acute lymphoblastic leukemia (ALL) and CLL. The companyÂ’s products also comprise UCART123 for acute myeloid leukemia indications and blastic plasmacytoid dendritic cell neoplasm; UCARTCS1 for multiple myeloma (MM) indications; UCART22 for ALL; and UCART38 for T-cell ALL and MM. In addition, it focuses on applying its gene-editing technologies to develop new generation plant products in the field of agricultural biotechnology. The company has strategic alliances with Pfizer Inc. to generate CAR T-cells in the field of oncology; Les Laboratoires Servier SAS to develop and commercialize product candidates; The University of Texas MD Anderson Cancer Center to research and develop novel cellular immunotherapies for patients suffering from various liquid tumors; and Cornell University to accelerate the development of a targeted immunotherapy for patients with acute myeloid leukemia. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.